a-D-Glucoheptonic acid calcium salt | 17140-60-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: a-D-Glucoheptonic acid calcium salt
• 英文别名: calcium;(2R,3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate
• CAS: 17140-60-2
• 化学式: C14H26CaO16
• 分子量: 490.42
• InChiKey: FATUQANACHZLRT-XBQZYUPDSA-L

物化性质

• 溶解度：
  水中 ≥ 89.2mg/mL，DMSO 中 ≥ 4.90mg/mL，温和加热

计算性质

• 辛醇/水分配系数(LogP)：
  -11.31
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  323
• 氢给体数：
  12
• 氢受体数：
  16

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• RTECS号：
  MA7980000

制备方法与用途

生物活性方面，NSC 42196 是一种内源性代谢产物。

文献信息

• ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH
  申请人：OssiFi Inc.

  公开号：US20140288068A1

  公开（公告）日：2014-09-25

  In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.

  在一个方面，该发明提供了式I的化合物，以及其盐、水合物和异构体。在另一个方面，该发明提供了一种通过向需要的受试者投予式I、式II或式III的化合物的治疗有效剂量来促进骨形成的方法。本发明还提供了骨科和牙周设备，以及使用式I、式II或式III的化合物治疗肾脏疾病和癌症的方法。
• PYRROLO - DIPYRIDINE COMPOUNDS
  申请人：OsteoQC Inc.

  公开号：US20200055853A1

  公开（公告）日：2020-02-20

  In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.

  在一个方面，本发明提供了化合物的公式I、公式Ia、公式Ib、公式Ic和公式Id以及它们的盐、水合物和异构体。在另一个方面，本发明提供了一种通过向需要的受试者施用公式I、公式Ia、公式Ib、公式Ic或公式Id的化合物的治疗有效量来促进骨形成的方法。本发明还提供了骨科和牙周病设备，以及使用公式I、公式Ia、公式Ib、公式Ic或公式Id的化合物治疗肾脏疾病、糖尿病骨质流失和癌症的方法。
• FLUORO BETA-CARBOLINE COMPOUNDS
  申请人：OsteoQC Inc.

  公开号：US20200054645A1

  公开（公告）日：2020-02-20

  In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

  在一个方面，该发明提供了化合物I的结构，以及其盐、水合物和异构体。在另一个方面，该发明提供了一种通过向需要的受试者施用化合物I的治疗有效量来促进骨形成的方法。本发明还提供了骨科和牙周设备，以及使用化合物I治疗肾脏疾病、糖尿病、骨质流失和癌症的方法。
• Diagnostic kit for blood pool imaging
  申请人：MERCK SHARP & DOHME (I.A.) CORP.

  公开号：EP0000253A1

  公开（公告）日：1979-01-10

  This invention relates to a method for efficiently labelling red blood cells, which permits the imaging of blood pools in the intact animal or human patient, accomplished by injection of a saline solution of an alkaline earth metal salt of glucoheptonic acid and a non-toxic stannous salt followed by injection with a solution of sodium pertechnetate Tc 99m to tag the red blood cells. The invention also relates to the kit used in the method of our invention, consisting of a single vial containing a lyophilized mixture of 25 mg. of calcium glucoheptonate and 3 mg. of stannous chloride dihydrate in 2 ml. of saline solution.

  本发明涉及一种对红细胞进行有效标记的方法，这种方法可以对完整的动物或人类患者的血池进行成像，具体做法是先注射葡萄糖庚酸的碱土金属盐和无毒锡盐的生理盐水溶液，然后注射过硫酸钠 Tc 99m 溶液对红细胞进行标记。 本发明还涉及用于本发明方法的试剂盒，该试剂盒由一个小瓶组成，小瓶中含有 25 毫克葡萄糖庚酸钙和 3 毫克二水氯化锡的冻干混合物以及 2 毫升生理盐水。
• Process for preparing oral calcium compositions
  申请人：Nycomed Pharma AS

  公开号：EP1743629A1

  公开（公告）日：2007-01-17

  The invention provides a process for the preparation of an orally administrable calcium composition, said process comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40µm, having a crystalline structure and having a surface area of 0.1 to 1.2 m2/g; (ii) mixing said calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and drying the resulting mixture to produce a first granulate; (iii) optionally mixing said first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing said first or second granulate to form tablets.

  本发明提供了一种用于制备口服钙组合物的工艺，所述工艺包括以下步骤：(i) 获得生理上可耐受的微粒钙化合物，其平均粒径范围为 3 至 40µm，具有结晶结构，表面积为 0.1 至 1.2 m2/g；(ii) 在流化床造粒装置中将所述钙化合物与水溶性稀释剂和水溶性粘合剂水溶液混合，并干燥所得混合物，以制备第一种颗粒；(iii) 可选地将所述第一种颗粒与一种或多种其它成分混合，以制备第二种颗粒；以及 (iv) 可选地压缩所述第一种或第二种颗粒，以形成片剂。